Rain On­col­o­gy's stock dives af­ter tu­mor treat­ment fails a PhI­II tri­al

Rain On­col­o­gy’s treat­ment for ded­if­fer­en­ti­at­ed li­posar­co­ma failed a Phase III clin­i­cal tri­al, rais­ing ques­tions about what’s next for the Bay Area biotech’s lead can­di­date.

On Mon­day, Rain On­col­o­gy un­veiled da­ta from its MANTRA tri­al in­ves­ti­gat­ing milademetan, an oral small mol­e­cule in­hibitor, in pa­tients with ded­if­fer­en­ti­at­ed li­posar­co­ma, a rare type of can­cer that is found in the soft tis­sue. The tri­al did not meet its pri­ma­ry end­point of pro­gres­sion-free sur­vival com­pared to tra­becte­din, the stan­dard of care. John­son & John­son mar­kets Yon­delis, the brand name ver­sion of tra­becte­din.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER